President Trump announced tariffs on Chinese imports Thursday, reigniting fears of a trade war and sending jitters through the the stock market.
“Even though this has been out there, the big worry is what’s the next shoe to drop,” said Daniel Ives, Chief Strategy Officer at GBH Insights.
The tariffs are aimed at curbing what Trump calls “a tremendous intellectual property theft problem.”
U.S. Trade Representative Robert Lighthizer now has 15 days to identify $50 billion worth of imports to tax, with a focus on technology products.
Many experts and investors fear that China will retaliate, impacting companies like Boeing that have carved large markets in China.
This move comes shortly after Trump levied taxes on imported steel and aluminium, angering allies around the world, including Canada and the EU.
Lighthizer signaled on Thursday that most of those allies will now be exempt from the metals tariffs, seeming to send a clear signal that much of Trump’s protectionist policies are squarely crafted with China in mind.
Overall, Chinese companies may have more to lose from these recent IP tariffs than U.S. tech companies, said Ives. He pointed out that, other than Amazon, revenue from China is negligible for most companies.
In addition to the tariff news, the markets were still reacting to Facebook’s privacy scandal.
The social media giant “continues to be that dark cloud over tech stocks,” said Ives.
“[It’s] been a lot of angst amongst investors we’ve been talking to.”
Meridith McGraw, White House Reporter at The Wall Street Journal, breaks down Trump’s $200M ballroom plan, D.C. police tensions, and the future of MAGA.
After years of being told that red wine was good for heart health, more Americans appear to be heeding warnings that even moderate alcohol consumption can be unhealthy.
Amazon is now rolling out a service where its Prime members can order their blueberries and milk at the same time as their batteries and other basic items.
Dr. Richard Besser, President & CEO of the Robert Wood Johnson Foundation and former CDC acting director, unpacks the impact of RFK's mRNA funding cuts.
Jessica Inskip, Director of Investor Research at StockBrokers.com and host of MarketMakeHer, unpacks earnings, market outlook, and what history says is next.
